McKesson Corporation (MCK) — 1Q FY2027 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is constructive — consensus sits modestly below the FY2027 guidance midpoint, the stock has re-rated sharply higher since the May print, and the single biggest swing factor is whether GLP-1 distribution volumes rebounded sequentially in the June quarter after the 4Q FY2026 dip.

Heading into the 1Q FY2027 print, the bar looks achievable but not easy. Consensus Adj. EPS of ~$9.55 sits roughly in line with the implied quarterly run-rate of the FY2027 guidance midpoint ($44.20), and management's own commentary on the May call flagged that the EPS cadence would be "broadly similar to FY2026 from a first-half, second-half perspective" — a signal that 1Q should not be a structurally weak quarter. Guidance tone has been consistently confident: FY2027 Adj. EPS of $43.80–$44.60 (12–14% growth, or 14–16% ex-Norway/Market Decisions items) was set at the upper end of the long-term target range, and management reiterated long-term segment operating profit growth targets across all four segments. Estimate revisions have been modestly negative since the May print — the 1Q FY2027 Adj. EPS consensus slipped from ~$9.63 to ~$9.55 — likely reflecting conservatism around the GLP-1 sequential volume recovery and IRA-related branded pricing headwinds that management explicitly flagged as a full-year revenue drag; importantly, neither item was expected to affect operating profit. The stock has surged ~17% since the May 7 earnings date (vs. XLV +12%, SPY +5%), suggesting the market has already priced in a solid execution story, which raises the bar for a positive surprise on the day. The key wildcard is the pace of GLP-1 volume recovery: a sequential rebound would validate management's "continued category growth" outlook and could drive upside to North American Pharma revenue, while a second consecutive sequential decline would likely pressure the stock despite the operating-profit-neutral framing.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — Adj. EPS of ~$9.55 is achievable given the guided cadence, but Oncology & Multispecialty operating profit is the higher-conviction swing factor given its above-market growth trajectory and acquisition integration tailwinds.

Table 1 — Current Quarter Snapshot (1Q FY2027, Quarter Ending June 30, 2026)

3. Guidance & Commentary Evolution

Key Takeaway: No formal guidance revisions since the May 7 earnings call — FY2027 Adj. EPS guidance of $43.80–$44.60 stands as initially set. Tone remains confident, with post-earnings actions (Medical-Surgical financing, share repurchase acceleration) reinforcing management's conviction in the capital return story.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly lower since the May 7 print — 1Q FY2027 Adj. EPS consensus fell ~−0.7% from the post-earnings baseline, and FY2027 Adj. EPS is essentially flat. The gap is small and likely reflects conservatism on GLP-1 volumes and IRA pricing, not a fundamental deterioration; consensus remains well within the guidance range.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of May 14, 2026 (5 trading days post-earnings). FY2027 guidance from MCK 4Q FY2026 Earnings Call Transcript and Earnings Release, May 7, 2026.

Estimates are broadly stable since the May print, with the modest EPS drift lower concentrated in 1Q rather than the full year — consistent with near-term GLP-1 and IRA uncertainty rather than a structural downgrade. The Oncology segment estimate has actually ticked slightly higher, reflecting continued confidence in acquisition integration momentum.

5. Stock Performance

Key Takeaway: MCK has significantly outperformed both XLV and the S&P 500 since the May 7 earnings date, with the move driven primarily by multiple re-expansion and positive sentiment around the Medical-Surgical separation and capital return acceleration — not estimate revisions, which have been flat to slightly negative.

Since the May 7, 2026 earnings date, MCK closed at $830.43 on August 5, 2026 (earnings day), representing a gain of approximately +10.0% from the $754.76 close on May 7. Over the same period, XLV gained approximately +12.1% (from $144.72 to $162.10) and SPY gained approximately +5.4% (from $731.58 to $771.33). MCK's peak intraday performance came around July 28, 2026 when the stock touched $889.50, a +17.8% gain from the May 7 close, before pulling back modestly into August. The stock's outperformance vs. SPY is notable; it has lagged XLV slightly on a raw basis, though MCK's beta to the healthcare sector is lower given its distribution-focused business model. The NTM P/E has expanded from approximately 17.1x at the May 7 close to approximately 17.8x currently, confirming that multiple re-rating — driven by the Medical-Surgical separation catalyst and $5B buyback announcement — has been the primary driver of returns, not EPS estimate revisions (which have been flat to slightly negative). Key events marked: June 12 ($2.25B Term B Loan for Med-Surg separation), July 1 (Chief Strategy Officer retirement/succession), July 16 (notable single-day rally of +5.6%), July 24 (Annual Shareholder Meeting).

Sector ETF used: XLV (Health Care Select Sector SPDR Fund) — appropriate for MCK given its classification as a healthcare services/distribution company within the S&P 500 Health Care sector.

Note: Stock performance chart (MCK vs. XLV vs. SPY indexed to 100 at May 7, 2026) based on closing price data from Yahoo Finance.

6. Material News & Developments

Key Takeaway: The most important post-earnings development is the completion of the $2.25B Medical-Surgical Term B Loan (June 12), which confirms the separation is on track and accelerates the $5B buyback program — a direct EPS tailwind for FY2027.

• June 9, 2026 — Medical-Surgical $2.25B Term B Loan Facility Closed (8-K, June 12, 2026). McKesson Medical-Surgical Top Holdings, Inc. entered into an amendment to its Credit Agreement to provide a $2.25B senior secured Term B Loan due 2032 at SOFR + 2.25%. This is a key milestone in the planned separation of the Medical-Surgical Solutions segment. Proceeds will be used to satisfy intercompany obligations with McKesson Corp. and deployed principally toward share repurchases, directly supporting the ~$5B FY2027 buyback target.
• June 29, 2026 — Chief Strategy & Business Development Officer Retirement (8-K, July 1, 2026). Thomas L. Rodgers (EVP, Chief Strategy & BDO) gave notice of retirement effective August 1, 2026. Ramesh Srinivasan appointed as EVP, Chief Strategy Officer effective August 1, 2026.
• June 24, 2026 — 1Q FY2027 Earnings Date Announced. McKesson confirmed August 5, 2026 as the 1Q FY2027 earnings release date, with results after market close.
• July 22, 2026 — Annual Shareholder Meeting (8-K, July 24, 2026). All directors elected; executive compensation and auditor approved. No material governance changes.
• May 7, 2026 (Earnings Call) — Apollo Minority Investment in Medical-Surgical. Definitive agreement for Apollo Funds to acquire ~13% minority interest in Medical-Surgical Solutions for $1.25B, valuing the NewCo at ~$13B enterprise value. McKesson retains operating control and majority ownership; Apollo ownership reflected as noncontrolling interest upon close.
• May 7, 2026 (Earnings Call) — $5B Share Repurchase Authorization. Board approved an additional $5B repurchase authorization in April 2026, bringing total authorization to ~$7.7B. Company plans to repurchase ~$5B of shares in FY2027, accelerated by Med-Surg financing proceeds.
• May 7, 2026 (Earnings Call) — CFO Transition. Britt Vitalone retired as CFO; Kenny Cheung (previously named successor) assumed the CFO role effective May 29, 2026. Vitalone remains as strategic advisor supporting the Medical-Surgical separation.
• May 7, 2026 (Earnings Call) — GLP-1 Revenue Headwind Flagged. Management noted GLP-1 distribution revenues declined 4% sequentially in 4Q FY2026 to $14B (still +22% YoY), and IRA-related branded pharmaceutical price declines reduced revenue growth by ~3 percentage points in the quarter. Critically, management stated neither had any impact on operating profit. FY2027 guidance assumes continued GLP-1 category growth with quarter-to-quarter variability.
• May 7, 2026 (Earnings Call) — US Oncology Network Expansion. Cancer Care Northwest added in April 2026, expanding the network across Washington and Idaho. PRISM Vision Group welcomed Retina Macula Institute (Southern California) effective May 1, 2026. US Oncology Network added 570+ providers in FY2026, the largest net increase since 2010.
• July 21, 2026 — Cardinal Health Acquires AdaptHealth Diabetes Unit + Strive Medical for ~$360M. Cardinal Health (CAH) announced acquisitions of AdaptHealth's diabetes health business ($235M) and Strive Medical, expanding its at-Home Solutions business. Leerink Partners called these "logical, strategic tuck-ins." Read-through for MCK: limited direct overlap, but signals continued consolidation in healthcare distribution/services.

7. Insider Transaction Activity

Key Takeaway: All insider transactions since the May 7 earnings date are 10b5-1 planned sales — no discretionary open-market selling and no open-market buying. The pattern is routine and obligation-driven; nothing signals unusual bearish conviction from insiders. Separately, retiring CFO Britt Vitalone filed a Form 144 notice of intended sale of ~$6.7M on August 3, 2026, consistent with his announced retirement.

Source: SEC Form 4 filings (Insider Transaction Data). Vitalone Form 144 from SEC EDGAR filing August 3, 2026.

8. Peer Commentary & Read-Through

Key Takeaway: No qualifying operational peer commentary from CAH or COR exists in the June 5 – August 4, 2026 window that addresses their current or forward reporting period. Both peers report imminently — COR reports August 5, 2026 (same day as MCK) and CAH reports August 11, 2026 — making their prints the most important near-term read-through catalysts for the pharmaceutical distribution sector.

Qualifying Peer Commentary (June 5 – August 4, 2026)

Scope applied: Only commentary published after each peer's last earnings call that addresses their current/forward reporting period (i.e., post-last-earnings developments, forward outlook, or current-quarter trends) is included. Commentary limited to previously completed-quarter results is excluded.

Cencora (COR) — Reporting 3Q FY2026 (Calendar Q2 2026) on August 5, 2026

No qualifying operational commentary found. The only COR documents identified in the research window are: (1) a July 1, 2026 press release announcing the 3Q FY2026 earnings date (August 5, 2026) — which contains no operational commentary, guidance, or market color; and (2) a June 15, 2026 8-K announcing the appointment of Samantha Hammock as new Chief Human Resources Officer — which contains no financial or operational content. No earnings call transcript, investor conference presentation, or 8-K with forward-looking operational commentary from COR was identified in the window.

Upcoming catalyst: COR reports 3Q FY2026 results on August 5, 2026 before market open — the same day as MCK's 1Q FY2027 earnings call. COR's commentary on pharmaceutical distribution volumes, specialty drug demand, GLP-1 trends, and IRA pricing impacts will be a direct and immediate read-through for MCK's print that evening.

Cardinal Health (CAH) — Reporting 4Q FY2026 (Calendar Q2 2026) on August 11, 2026

No qualifying operational commentary found. The only CAH document identified in the research window is a July 9, 2026 press release announcing the 4Q FY2026 earnings date (August 11, 2026) — which contains no operational commentary, guidance, or market color. No earnings call transcript, investor conference presentation, or 8-K with forward-looking operational commentary from CAH was identified in the window.

The one notable CAH development in the window is a July 21, 2026 announcement that CAH agreed to acquire AdaptHealth's diabetes health business and Strive Medical for a combined ~$360M. This is a strategic/M&A development rather than operational commentary on the current quarter, and its read-through for MCK is limited (different business lines). Leerink Partners described the deals as "logical, strategic tuck-ins" for CAH's at-Home Solutions business.

Upcoming catalyst: CAH reports 4Q FY2026 results on August 11, 2026. CAH's commentary on pharmaceutical distribution demand, specialty volumes, GLP-1 trends, and pricing dynamics will be a key post-MCK read-through for the sector.

Broader Healthcare Sector Read-Throughs (Relevant to MCK's End Markets)

While CAH and COR have not provided qualifying operational commentary, several broader healthcare sector prints in the last 60 days offer relevant read-throughs for MCK's key themes:

Sources: News Digest (Implied platform), SEC filings (8-K, earnings releases), and press releases as cited above. All commentary is from the June 5 – August 4, 2026 window and addresses current or forward reporting periods.